Dallas, TX – December 11, 2019 — – Puration, Inc. (OTC Pink: PURA) today confirmed an update with more details on the company’s recently announced expansion plan scheduled for next week on Tuesday, December 17, 2019. PURA’s expansion is intended to substantially increase PURA’s 2020 prospects beyond its current $8 million revenue target. PURA has recently reconfirmed its $4 million revenue target for 2019 and an $8 million revenue target for 2020. The CBD beverage market is one of the fastest growing beverage sectors anticipated to reach $1.4 billion by 2023.
After introducing its flagship beverage, EVERx CBD Sports Water well over two years ago and going on to later introduce new CBD infused beverages now coming to market, PURA is taking inventory of its experience and corresponding know-how and realizing it has amassed resources with the potential to deliver even more value to shareholders than just supporting the ongoing growth of its own beverage brands. While the recent business acquisitions in Europe and Latin American combined with the business partnerships in Canada and South Africa have expanded the companies capacity to deliver its own beverages on four different continents, the acquisitions have also expanded PURA’s capacity to delivery even more opportunity separate from its current line of beverages.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.